​​The core uses a patent-pending, modified mRNA/miRNA-based method to reprogram somatic cells into induced pluripotent stem cells (iPSCs). This cutting-edge technology was developed by the co-directors of the core, Drs. Kogut and Bilousova (High-efficiency RNA-based reprogramming of human primary fibroblasts. Nature Communications. (2018). It provides the following significant advantages over traditional cell reprogramming approaches such as lentiviral-, episomal-, and Sendai virus-based methods:​

  • non-integrative
  • ultra-high yield (up to 90%)
  • cost effective


We provide up to 5 early passage iPSC clones per reprogrammed cell line (2 vials per clone)

Fibroblast reprogramming

Primary fibroblast lines provided by a customer, or isolated by the core from provided skin biopsies, are reprogrammed into iPSCs. Our protocol is approximately 18 days (iPSC colonies can be seen as early as day 13). If desired, a complete characterization profile can be provided post reprogramming.


​Fibroblast Isolation From Skin Biopsy​2 weeks
​Fibroblast Reprogramming​2-3 weeks
​iPSCs culturing and expansion​2 weeks
​Mycoplasma test​1 week
​Pluripotency Staining​1 week
​Karyotyping​​4 weeks

Renal cell reprogramming

The core personnel is skilled in developing primary renal epithelial cell (REC) lines from human urine specimens and reprogramming REC lines into iPSCs. Please contact us​ for more information.

Note: a copy of approved IRB protocol(s) must be provided by customers before reprogramming patient-derived cells